Cigna's Plan to Shift from Drug Rebates: What it Could Mean for Pharmacy Strategy — and a Call to Action for Smarter Pharmacy Strategy

Cigna's announcement to shift away from prescription drug rebates for its fully insured plans in 2027 and for Express Scripts' customers in 2028 is another signal of ongoing change in how pharmacy economics may be structured in the future. The transition from post-sale rebates to up-front discounts has the potential to redefine how value is measured across the drug supply chain but the ultimate impact on payers, members, and overall drug costs remains uncertain. This shift reinforces the need for clear strategies and accountability as stakeholders navigate the evolving marketplace and underscores the urgent need for transparency, innovation, and accountability.

At Expion Health, those principles aren't new. They're foundational.

Transparency and Independence at Our Core

From day one, Expion Health was built to challenge the traditional PBM model — a model too often shaped by opaque contracts and conflicting financial incentives. Our commitment to transparency and independence allows us to focus purely on what matters: delivering the lowest net cost and ensuring patients can afford the medications they need.

Staying Ahead of Industry Change

The pharmacy landscape is shifting faster than ever and Cigna's announcement is just one sign of how rapidly the pharmacy landscape is evolving. At Expion Health, we don't just respond to change — we anticipate it.

Our team continuously tracks the forces transforming pharmacy economics, from direct-to-consumer strategies and biosimilar expansion to emerging legislative and regulatory shifts.

ExpionIQ: Powering a Multi-Channel Approach

Our award-winning ExpionIQ platform is uniquely designed to optimize the lowest net cost across all channels. By integrating data, analytics, and actionable insights, ExpionIQ helps clients capture savings from every available opportunity — from manufacturer discount programs to evolving biosimilar strategies and direct-to-consumer pathways.

The Role and Reassessment of Rebates

Rebates have long played a central role in how plans manage drug costs, but they've also added complexity and obscured true pricing transparency. Any move away from rebates, including Cigna's new approach, must be carefully evaluated to determine whether it delivers genuine value or simply redistributes costs within the system.

The Bottom Line

Cigna's move underscores what Expion Health has long known: the future of pharmacy benefits is transparent, data-driven, and patient-centered. With ExpionIQ, our clients are already equipped to thrive in this new reality by leveraging a multi-channel approach to navigate cost-of-goods dynamics, capture real savings, and drive affordability for the members who depend on them.

Want to explore how Expion can help you navigate pharmacy benefit changes and lower costs? Connect with us here.